Consultation on the commercial release of a genetically modified (GM) mosquito strain (DIR 207)

Between 14 May and 7 July 2025, we sought your feedback on the consultation version of the Risk Assessment and Risk Management Plan (RARMP) prepared for the DIR 207 licence application from Oxitec Australia Pty Ltd (commercial release of a genetically modified (GM) mosquito strain to help prevent dengue outbreaks).

During the 55-day consultation period, we received advice from prescribed Government agencies, local government areas, the Gene Technology Technical Advisory Committee and from the public.

We heard support for:

• the release of the GM mosquitoes.
• the uncertainties identified in the RARMP.
• the overall conclusions of the RARMP.

We also heard concerns for:

• the potential negative impact on people and the environment.
• the effectiveness and need for the GM technology.
• the potential impact on existing dengue control strategies.

The applicant has decided to withdraw the application, and no decision was made.